Glemont chewing tablets 5 mg. №30


Manufacturer: India

Additional treatment of bronchial asthma in patients with persistent asthma from mild to moderate, which is insufficiently controlled by inhaled corticosteroid drugs, as well as with insufficient clinical control of asthma using short-acting β-agonists, used if necessary. Symptomatic treatment of seasonal allergic rhinitis in patients with bronchial asthma. Prevention of asthma, the dominant component of which is bronchospasm induced by physical exertion. Relief of symptoms of seasonal and year-round allergic rhinitis.



Glemont chewing Composition

active substance: montelukast

1 tablet contains montelukast sodium equivalent to montelukast 4 mg or 5 mg

Excipients: microcrystalline cellulose, beckons (E 421), croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, aspartame (E 951), cherry flavor.

Glemont chewing Dosage form

Chewable tablets.

Basic physical and chemical properties:

Glemont chewing Pharmacological group

Anti-asthma drugs for systemic use. Leukotriene receptor antagonists.

ATX code R03D C03.

Pharmacological properties


Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids secreted by a variety of cells, including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene receptors (CysLT) present in the human respiratory tract and cause reactions such as bronchospasm, sputum production, vascular permeability and increased eosinophil count.

Treatment with montelukast suppresses bronchospasm both in the early and late stages, reducing the response to antigens. Montelukast, compared with placebo, reduces the number of peripheral blood eosinophils in adults and children. In a separate study, taking montelukast significantly reduced the number of eosinophils in the airways (as measured by sputum). In adult patients and children aged 2 to 14 years, montelukast, compared with placebo, reduces the number of peripheral blood eosinophils and improves the clinical control of asthma.


4 mg Montelukast Chewable Tablets are recommended for children 2 to 5 years of age.

Montelukast chewable tablets 5 mg are recommended for children from 6 to 14 years old:

as an alternative method of treatment instead of low doses of inhaled corticosteroids for patients with persistent mild asthma who have not recently had severe asthma attacks requiring oral corticosteroids, as well as for those patients who are found to be intolerant to inhaled corticosteroids
as the prevention of asthma, the dominant component of which is exercise-induced bronchospasm
to relieve symptoms of seasonal and perennial allergic rhinitis.


Hypersensitivity to the components of the drug.